Gonococcal Infections Gonococcal Infections
Conditions
Interventions
Group B meningococcal vaccine Bexsero will be administered on the date of enrollment in the study, with a second dose 4 weeks later. Sexually transmitted disease testing will be performed every 3 mont
C570015
Sponsors
Aoki Takahiro
Eligibility
Sex/Gender
Male
Inclusion criteria
Inclusion criteria: (1)Adult MSM aged 18 years or older who are regular attendees at ACC or SH outpatient clinics (2)Patients with a history of bacterial STI (syphilis, gonorrhea, or chlamydia) in the past 2 years (3) Those who have given written consent to participate in the study.
Exclusion criteria
Exclusion criteria: (1)Those who are allergic to meningococcal B vaccine Bexsero (2)Patients with contraindications to intramuscular injection of the vaccine due to abnormalities in the blood coagulation system, etc. (3)Patients with a history of Bexsero administration (4)gonococcal infection positive at screening (5)Those who have received doxycycline within two weeks of registration (6)Other conditions that make participation in the study inappropriate for the patient.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Preventive efficacy of group B meningococcal vaccine Bexsero in preventing gonococcal infections. | — |
Secondary
| Measure | Time frame |
|---|---|
| Effect of Bexsero prophylaxis on other bacterial STIs. VE in the presence of overlapping other bacterial STIs. VE in the presence of HIV infection. Collecting Bexsero adverse events. | — |
Contacts
Public ContactTakahiro Aoki
National Center for Global Health and Medicine, Japan Institute for Health Security
Outcome results
None listed